TABLE 1.

Study characteristics.

Study	Regestion number	Design	Treatment	No. of patients	Age range	Male/female (n)	Previous therapy	NO. of patients received ASCT,n (%)	mPFS (m)	MINORs scores	Ref
Andrzej J. Jakubowiak-2019	NCT02199665	Phase I, single arm	SEL + DEX + CFZ	21	55–74	11/10	2–10	20 (95%)	3.7	12	Jakubowiak et al. (2019)
Bahlis, N. J.-2019	NCT02343042	Phase Ib/II, single arm	SEL + DEX + BTZ	42	43–75	23/19	1–11	30 (71%)	9.0	14	Bahlis et al. (2018)
Grosicki, S.-2020	NCT03110562	Phase III, randomized study	SEL + DEX + BTZ	195	59–72	115/80	1–3	76 (39%)	13.93	RCT	Grosicki et al. (2020)
Meghan Salcedo. -2020	—	Phase I, single arm	SEL + DEX + IXZ	18	44–78	10/8	1–11	15 (83%)	-	10	Salcedo et al. (2020)
Chari A.-2019	NCT02336815	Phase IIb, single arm	SEL + DEX	122	40–86	71/51	3–18	102 (84%)	3.7	16	Chari et al. (2019)
Dan T. Vogl-2018	NCT02336815	Phase II, single arm	SEL + DEX	79	34–78	37/42	3–17	61 (77%)	2.3	16	Vogl et al. (2018)

BTZ, bortezomib; CFZ, carfilzomib; DEX, dexamethasone; IXZ, ixazomib; RCT, randomized controlled trail; SEL, Selinexor.